

Ref. No.: WOCK/SEC/SE/2026-27/007

4th May, 2026

BSE Limited Corporate Relations Department P J Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 532300	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: WOCKPHARMA
---	--

Dear Sir/ Madam,

Subject: Outcome of the Board Meeting held on 4th May, 2026

Pursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('**Listing Regulations**'); and in continuation to our letter bearing reference no. Ref. No.: WOCK/SEC/SE/2026-27/006 dated 28th April, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 4th May, 2026, *inter-alia*, has approved:

- i. the Audited Financial Results and Financial Statements (Standalone & Consolidated) for the quarter and financial year ended 31st March, 2026. Kindly find enclosed herewith:
 - a. Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended 31st March, 2026 along with Audit Report issued by M/s. M S K C & Associates LLP, Statutory Auditors of the Company on the same (enclosed as **Annexure I**); and
 - b. Declaration on unmodified opinion on Audit Report (enclosed as **Annexure II**)
- ii Enabling proposal for raising of funds by issue of equity shares / securities convertible into equity shares/ non-convertible securities or any combination thereof in one or more tranches of public and/or private offerings, Qualified Institutions Placement and/or on preferential allotment basis or any combination thereof or any other method as may be permitted under applicable law, subject to consent of the shareholders at the ensuing Annual General Meeting and such approvals and compliances as may be required.

The above information is also available on the website of the Company i.e <https://www.wockhardt.com>.

The meeting of the Board of Directors commenced at 11:00 a.m. and concluded at 3:10 p.m.

Kindly take the same on record.

For **Wockhardt Limited**

Rashmi Mamtura
Company Secretary
Encl: a/a

INDEPENDENT AUDITOR'S REPORT**To the Board of Directors of Wockhardt Limited****Report on the Audit of the Standalone Annual Financial Results****Opinion**

We have audited the accompanying standalone annual financial results of Wockhardt Limited (hereinafter referred to as 'the Company') for the year ended March 31, 2026, ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

(i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(ii) gives a true and fair view, in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the net profit, and other comprehensive income and other financial information of the Company for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the standalone financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Standalone Financial Results

This Statement has been prepared on the basis of the standalone annual financial statements. The Company's Management and Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit, and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the applicable



MSKC & Associates LLP

Chartered Accountants

Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are



MSKC & Associates LLP

Chartered Accountants

inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For M S K C & Associates LLP
Chartered Accountants

ICAI Firm Registration Number: 0015955/S000168



Bhavik L. Shah
Partner

Membership No. 122071

UDIN: 26122071KMFYDD5145



Place: Mumbai

Date: May 04, 2026

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006

Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

CIN:L24230MH1999PLC120720

Tel: 91 22 2653 4444 ; Fax: 91 22 2652 3905; e-mail id : investorrelations@wockhardt.com; Website: www.wockhardt.com

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(Rs in Crore except per share data)

PARTICULARS (Refer notes below)	3 MONTHS ENDED 31/03/2026	3 MONTHS ENDED 31/12/2025	3 MONTHS ENDED 31/03/2025	YEAR ENDED 31/03/2026	YEAR ENDED 31/03/2025
	Audited (Refer note 3)	Unaudited	Audited (Refer note 3)	Audited	Audited
1 Income					
(a) Revenue from operations	516	430	355	1,739	1,402
(b) Other income	55	27	14	137	55
Total income	571	457	369	1,876	1,457
2 Expenses					
(a) Cost of materials consumed	79	81	76	309	310
(b) Purchase of stock-in-trade	40	67	44	198	172
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	1	(38)	(35)	(92)	(46)
(d) Employee benefits expense	79	78	64	313	262
(e) Finance costs	41	50	40	176	199
(f) Depreciation and amortisation expense	43	52	40	186	168
(g) Other expenses	156	129	100	494	404
Total expenses	439	419	329	1,584	1,469
3 Profit/(Loss) before exceptional items and tax (1-2)	132	38	40	292	(12)
4 Exceptional items- credit/(charge) - refer note 2	35	(10)	-	25	-
5 Profit/(Loss) before tax (3 ± 4)	167	28	40	317	(12)
6 Tax expense:					
Current tax	-	-	-	-	-
Deferred tax	-	-	-	-	-
7 Net Profit/(Loss) after tax (5 ± 6)	167	28	40	317	(12)
8 Other Comprehensive Income:					
i) Items that will not be reclassified to Profit or Loss - credit/(charge) (consisting of re-measurement of net defined benefit liability)	1	(1)	(0.13)	0.08	(1)
ii) Income tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-
iii) Other Comprehensive Income (net of tax) (8i ± 8ii)	1	(1)	(0.13)	0.08	(1)
9 Total Comprehensive Income (7 ± 8(iii))	168	27	40	317	(13)
10 Paid-up equity share capital (face value of Rs. 5/- each)	81	81	81	81	81
11 Other Equity excluding Revaluation Reserves as per balance sheet				3,003	2,682
12 Earnings per share (face value of Rs. 5/- each) (*not annualised)					
(a) Basic (Rs.)	10.29*	1.73*	2.47*	19.54	(0.76)
(b) Diluted (Rs.)	10.28*	1.73*	2.47*	19.52	(0.76)



(Handwritten signature)

Notes to Standalone results :-

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 04, 2026. The Statutory Auditors have expressed an unmodified audit opinion with respect to the Audited Financial Results of the Company for the year ended March 31, 2026.

- 2) a) Settlement of Legal Dispute (Dr. Reddy's Laboratories) : The Company had previously concluded a Business Transfer Agreement ("BTA") with Dr. Reddy's Laboratories Limited ("Purchaser") on February 12, 2020, with further amendments thereto, for the transfer of a portion of its Domestic Branded Division. Out of the total consideration of Rs. 1,850 Crores, an amount of Rs. 300 Crores was designated as a "Holdback Amount" to be released contingent upon the Business Undertaking achieving specific revenue benchmarks.
The Company entered into a settlement agreement with Purchaser towards full and final settlement of all claims and disputes under BTA and legal proceedings effective March 31, 2026 and recognized net gain of Rs. 35 crore under 'Exceptional Items' for the quarter ended March 31, 2026.

b) Impact of New Labour Codes:
Effective November 21, 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes ('Code'). All set of rules under the Code are yet to be notified.
The Company has assessed and accounted the incremental impact of the new Code based on the best available information and actuarial valuation amounting to Rs. 10 Crores as 'Exceptional items'. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

- 3) Figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures of the full financial year and the reviewed figures upto the third quarter of the relevant financial year.

- 4) The Company is exclusively into Pharmaceutical business segment.

Mumbai
Date: May 04, 2026



FOR WOCKHARDT LIMITED


H.F. KHORAKIWALA
CHAIRMAN
DIN:00045608



STATEMENT OF STANDALONE ASSETS AND LIABILITIES

(Rs. in Crore)

	PARTICULARS	As at 31/03/2026 Audited	As at 31/03/2025 Audited
A)	ASSETS		
	1 Non- Current assets		
	(a) Property, plant and equipment	907	983
	(b) Right of use assets	221	257
	(c) Capital work-in-progress	121	79
	(d) Intangible assets	224	36
	(e) Intangible assets under development	1,276	1,181
	(f) Financial assets		
	(i) Investments in subsidiaries	297	297
	(ii) Other Investments *	0	0
	* Rs. 0.45 crore (Previous year - Rs. 0.45 crore)		
	(iii) Other non-current financial assets	73	52
	(g) Deferred tax assets (Net)	250	250
	(h) Non-current tax assets (Net)	78	75
	(i) Other non-current assets	107	104
	Sub-total- Non-current assets	3,554	3,314
	2 Current assets		
	(a) Inventories	533	426
	(b) Financial assets		
	(i) Investments	412	422
	(ii) Trade receivables	846	612
	(iii) Cash and cash equivalents	76	35
	(iv) Bank balances (other than Cash and cash equivalents)	31	78
	(v) Other current financial assets	103	85
	(c) Other current assets	289	332
	Sub-total - Current assets	2,290	1,990
	3 Assets held-for-sale	91	104
	TOTAL ASSETS	5,935	5,408
B)	EQUITY AND LIABILITIES		
	1 Equity		
	(a) Equity share capital	81	81
	(b) Other Equity	3,003	2,682
	Sub-total- Equity	3,084	2,763
	2 Liabilities		
	I. Non- Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	1,244	937
	(ii) Lease Liabilities	141	195
	(b) Provisions	40	30
	Sub-total- Non-current liabilities	1,425	1,162
	II. Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	501	590
	(ii) Lease Liabilities	78	74
	(iii) Trade payables		
	a. Total outstanding dues of micro enterprises and small enterprises	85	47
	b. Total outstanding dues of creditors other than micro enterprises and small enterprises	418	429
	(iv) Other current financial liabilities	189	93
	(b) Other current liabilities	120	218
	(c) Provisions	33	30
	(d) Current tax liabilities (Net)	2	2
	Sub-total- Current liabilities	1,426	1,483
	Total Liabilities	2,851	2,645
	TOTAL EQUITY AND LIABILITIES	5,935	5,408



FOR WOCKHARDT LIMITED

H F KHORAKI WALA
H F KHORAKI WALA
CHAIRMAN
DIN: 00045608

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

STANDALONE AUDITED CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2026

(Rs. in Crore)		
PARTICULARS	YEAR ENDED 31/03/2026	YEAR ENDED 31/03/2025
(Refer notes below)	Audited	Audited
Cash flow from/(used in) Operating activities		
Profit/(Loss) before tax	317	(12)
Adjustments for:		
Depreciation and amortisation expense	186	168
Allowance for expected credit loss, doubtful advances and bad debts	17	9
Profit on sale of fixed assets (net)	(55)	(3)
Gain on sale of investments	(17)	(11)
Finance costs	176	199
Foreign exchange fluctuation gain, net	(32)	(4)
Interest income	(7)	(9)
Employee share based payments expenses	4	1
Liabilities no longer required written back	-	(22)
Fair valuation impact on investments	(13)	(7)
Operating profit before working capital changes	576	309
Movements in Working capital		
Increase in Inventories	(107)	(105)
Increase in Trade receivables	(202)	(42)
Decrease/(Increase) in Loans and Advances and other assets	26	(167)
(Decrease)/Increase in Liabilities and provisions	(57)	70
Increase/ (Decrease) in Trade payables	8	(106)
Cash from/(used in) operations	244	(41)
Income tax (paid) /refund (net)	(3)	27
Net cash inflow/(outflow) from Operating activities	241	(14)
Cash flow from/(used in) Investing activities		
Purchase of property, plant and equipment and capital work-in progress	(86)	(41)
Proceeds from sale of property, plant and equipment, including Asset held- for -sale	53	10
Guarantee commission received	3	36
Purchase of Intangible assets and Intangible assets under development	(234)	(463)
Sale/(Purchase) of current investments (net)	39	(404)
Margin money under lien and Bank balances (other than cash and cash equivalents)	29	(41)
Interest received	3	3
Net cash outflow from Investing activities	(193)	(900)
Cash flow from/(used in) Financing activities		
Proceeds from Issuance of Equity share capital under Qualified Institutional Placement (QIP), net	-	983
Transaction cost related to QIP/Right Issue concluded during earlier years	-	(1)
Proceeds from Issuance of Equity share capital under ESOS* [* Rs. 0.003 crore (Previous year- Rs. 0.02 crore)]	0	0
Proceeds from Long-term borrowings	600	50
Repayment of Long-term borrowings	(99)	(97)
Short-term borrowings (net)	(50)	(288)
Loans from Related parties- Long term	137	380
Repayment of loans taken from Related parties- Long term	(325)	(333)
Repayment of loans taken from Related parties- Short term	(42)	(45)
Repayment of Lease liabilities (refer note 2 below)	(79)	(75)
Finance costs paid	(149)	(88)
Net cash (outflow)/inflow from Financing activities	(7)	486
Net Decrease in Cash and Cash equivalents	41	(428)
Cash and cash equivalents as at the beginning of the year	35	463
Cash and cash equivalents as at the end of the year	76	35



(Handwritten Signature)



Reconciliation of cash and cash equivalents as per the cash flow statement:

(Rs. in Crore)

	As at 31/03/2026	As at 31/03/2025
Cash and cash equivalents as per above comprise of the following:		
Cash	-	-
Balance with banks:		
- in current account	76	35
Balance as per the Statement of cash flows	76	35

Notes:

1. The above statement of cash flows has been prepared under the indirect method as set out in Ind AS 7 'Statement of Cash Flows'.

2. Repayment of lease liabilities consists of:

Payment of interest Rs. 23 crore (Previous period - Rs. 27 crore)

Payment of Principal Rs. 56 crore (Previous period - Rs. 48 crore)

3. Figures in bracket indicate cash outflow.

FOR WOCKHARDT LIMITED



H F KIIRAKIWALA
CHAIRMAN
DIN: 00045608

Mumbai

Date: May 04, 2026



INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Wockhardt Limited

Report on the Audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Wockhardt Limited (hereinafter referred to as the 'Company' or the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended March 31, 2026, ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiaries, the aforesaid Statement:

(i) includes the annual financial results of the Holding Company and the entities enumerated in Annexure 1 to this report

(ii) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of the consolidated net profit, and consolidated other comprehensive income and other financial information of the Group, for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the consolidated financial results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.



MSKC & Associates LLP

Chartered Accountants

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

This Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Management and Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the consolidated net profit, and consolidated other comprehensive income and other financial information of the Group, in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and is in compliance with the Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Management and Board of Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group and are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material



MSKC & Associates LLP

Chartered Accountants

misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.



MSKC & Associates LLP

Chartered Accountants

Other Matters:

The Statement includes the audited financial results of 17 subsidiaries whose financial results (before consolidation adjustments) reflect total assets of Rs. 4,803 Crores as at March 31, 2026, total revenue of Rs. 3,082 Crores, net loss after tax of Rs. 25 Crores, total comprehensive income of Rs. 45 Crores and net cash inflow of Rs. 53 Crores for the year ended on that date respectively, as considered in the Statement, which have been audited by the other auditors. The other auditors' reports on the financial results of these entities have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of such other auditors and the procedures performed by us are as stated in paragraph above.


The Statement includes the unaudited financial results of 7 subsidiaries whose financial results (before consolidation adjustments) reflect total assets of Rs. 129 Crores as at March 31, 2026, total revenue of Rs. 21 Crores, net profit after tax of Rs. 3 Crores, total comprehensive income of Rs. 3 Crores, and net cash inflow of Rs. 4 Crores for the year ended on that date respectively, as considered in the Statement. These unaudited financial results have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on such unaudited financial results. In our opinion and according to the information and explanations given to us by the Management, these financial results are not material to the Group.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For M S K C & Associates LLP
Chartered Accountants

ICAI Firm Registration Number: 0015955/5000168



Bhavik L. Shah

Partner

Membership No. 122071

UDIN: 26122071NWYOU8205



Place: Mumbai

Date: May 04, 2026

MSKC & Associates LLP

Chartered Accountants

Annexure 1 - List of entities included in the results

Sr No.	Name of Entities
1	Wockhardt UK Holdings Limited
2	CP Pharmaceuticals Limited
3	CP Pharma (Schweiz) AG
4	Wallis Group Limited
5	The Wallis Laboratory Limited
6	Wockhardt Farmaceutica Do Brasil Ltda
7	Wallis Licensing Limited
8	Wockhardt Infrastructure Development Limited
9	Z & Z Services GmbH
10	Wockhardt Europe Limited
11	Wockhardt Nigeria Limited
12	Wockhardt USA LLC (upto 11th July 2025)
13	Wockhardt UK Limited
14	Wockpharma Ireland Limited
15	Pinewood Laboratories Limited
16	Pinewood Healthcare Limited
17	Wockhardt Holding Corp.
18	Morton Grove Pharmaceuticals Inc. (upto 11th July 2025)
19	MGP Inc.
20	Wockhardt Farmaceutica SA DE CV
21	Wockhardt Services SA DE CV
22	Wockhardt Bio AG
23	Wockhardt Bio (R) LLC
24	Wockhardt Bio Pty Limited
25	Wockhardt Bio Limited
26	Wockhardt Medicines Limited
27	Wockhardt Bioscience Limited (Formerly, Wockhardt Bionova Limited)
28	Wockhardt Antibiotics (Ireland) Limited (w.e.f. April 07, 2025)
29	Wockhardt Suisse AG (w.e.f. December 01, 2025)
30	Wockhardt Suisse USA Holding Corporation (w.e.f. December 11, 2025)
31	Wockhardt Suisse USA LLC (w.e.f. December 11, 2025)



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhajl Nagar - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051
CIN: L24230MH1999PLC120720

Tel: 91 22 2653 4444; Fax: 91 22 2652 3905; e-mail id: investorrelations@wockhardt.com, Website: www.wockhardt.com

(Rs. In Crore except per share data)						
STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026						
	PARTICULARS	3 MONTHS ENDED 31/03/2026	3 MONTHS ENDED 31/12/2025	3 MONTHS ENDED 31/03/2025	YEAR ENDED 31/03/2026	YEAR ENDED 31/03/2025
	(Refer Notes Below)	Audited (Refer note 5)	Unaudited	Audited (Refer note 5)	Audited	Audited
1	Income					
	(a) Revenue from operations	965	888	743	3,373	3,012
	(b) Other income	45	25	15	111	62
	Total income	1,010	913	758	3,484	3,074
2	Expenses					
	(a) Cost of materials consumed	177	170	159	674	612
	(b) Purchase of stock-in-trade	156	161	148	586	573
	(c) Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	(15)	(14)	(47)	(128)	(53)
	(d) Employee benefits expense	187	181	166	725	651
	(e) Finance costs	50	60	48	213	254
	(f) Depreciation and amortisation expense	53	65	53	227	217
	(g) Exchange fluctuation loss, net	(29)	(4)	15	(22)	4
	(h) Other expenses	264	217	238	886	832
	Total expenses	843	836	780	3,161	3,090
3	Profit /(Loss) before exceptional items and tax (1-2)	167	77	(22)	323	(16)
4	Exceptional items- charge (Note 4)	22	(10)	-	(85)	-
5	Profit /(Loss) after exceptional items and before tax (3 ± 4)	189	67	(22)	238	(16)
6	Tax expense:					
	Current tax - charge	5	6	1	18	7
	Deferred tax - charge/ (credit) - (Net)	20	-	22	21	34
7	Net Profit /(Loss) after tax (5 ± 6)	164	61	(45)	199	(57)
	Attributable to :					
	Equity shareholders of the Company	166	59	(25)	213	(47)
	Non - Controlling Interest	(2)	2	(20)	(14)	(10)
8	Other Comprehensive Income					
	(a) Items that will not be reclassified to Profit or Loss - (charge)/ credit (consisting of re-measurement of net defined benefit (liability) / asset)	71	(0.72)	(5)	70	(6)
	(b) Income tax relating to items that will not be reclassified to Profit or Loss - credit/(charge)	-	-	1	-	1
	(c) Items that will be reclassified to Profit or Loss - (charge)/ credit (Consisting of Exchange differences on translating the financial statements of foreign operations)	79	29	60	349	76
	(d) Other Comprehensive Income (net of tax) (a ± b ± c)	150	28	56	419	71
9	Total Comprehensive Income (7 ± 8 (d))	314	89	11	618	14
	Other Comprehensive Income attributable to :					
	Equity shareholders of the Company	121	23	36	368	60
	Non - Controlling Interest	29	5	20	51	11
		150	28	56	419	71
	Total Comprehensive Income attributable to :					
	Equity shareholders of the Company	287	82	11	581	13
	Non - Controlling Interest	27	7	-	37	1
		314	89	11	618	14
10	Paid-up equity share capital (face value of Rs. 5/- each)	81	81	81	81	81
11	Other Equity excluding Revaluation Reserves as per Balance Sheet				4,860	4,272
12	Earnings per equity share (face value of Rs. 5/- each)					
	(*not annualised)					
	(a) Basic (Rs.)	10.23*	3.61*	(1.57)*	13.12	(3.02)
	(b) Diluted (Rs.)	10.22*	3.61*	(1.57)*	13.10	(3.02)



[Handwritten Signature]



Notes To Consolidated Results:-

1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 04, 2026. The Statutory Auditors have expressed an unmodified audit opinion with respect to the Audited Financial Results of the Company for the year ended March 31, 2026.

2) The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute 'the Group') and are prepared by applying Ind AS 110 - "Consolidated Financial Statements".

3) **Key Financials on Standalone basis:**

(Rs. In Crore)

PARTICULARS	3 MONTHS ENDED 31/03/2026	3 MONTHS ENDED 31/12/2025	3 MONTHS ENDED 31/03/2025	YEAR ENDED 31/03/2026	YEAR ENDED 31/03/2025
	Audited (Refer note 5)	Unaudited	Audited (Refer note 5)	Audited	Audited
Total Income	571	457	369	1,876	1,457
Profit (Loss) before tax	167	28	40	317	(12)
Profit (Loss) after tax	167	28	40	317	(12)

Note: The audited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com) and also on the Company's website www.wockhardt.com.

4) Exceptional items for the financial year ended March 31, 2026, amount to a net charge of Rs. 85 Crores. This comprises the following:

a) Deconsolidation of US Subsidiaries

During the year, the Group has taken decision to exit the US generic pharmaceutical business. Accordingly, Wockhardt had filed for voluntary liquidation on July 11, 2025 under Chapter 7 of the US Bankruptcy Code for its US step down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, both incorporated in Delaware. Pursuant to such application, the court has appointed trustee to oversee winding up process of the subsidiaries. Consequently, the Group has lost control over these subsidiaries as per Ind AS 110 "Consolidated Financial Statement" w.e.f. July 11, 2025. The Group recognized an initial charge of Rs. 97 Crores under Exceptional Items for the quarter ended September 30, 2025 in relation to deconsolidation including impairment of investments, and intercompany receivables of the Group.

Further, during the current quarter, the Group has executed settlement agreement with chapter 7 trustee for the bankruptcy estate resulting in net additional charge of Rs. 13 Crores which has been recognized under Exceptional Items for the quarter ended March 31, 2026.

b) Settlement of Legal Dispute (Dr. Reddy's Laboratories)

The Company had previously concluded a Business Transfer Agreement ("BTA") with Dr. Reddy's Laboratories Limited ("Purchaser") on February 12, 2020, with further amendments thereto, for the transfer of a portion of its Domestic Branded Division. Out of the total consideration of Rs. 1,850 Crores, an amount of Rs. 300 Crores was designated as a "Holdback Amount" to be released contingent upon the Business Undertaking achieving specific revenue benchmarks.

The Company entered into a settlement agreement with Purchaser towards full and final settlement of all claims and disputes under BTA and legal proceedings effective March 31, 2026 and recognized net gain of Rs. 35 Crores under Exceptional Items for the quarter ended March 31, 2026.

c) Impact of New Labour Codes

Effective November 21, 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes ('Code'). All set of rules under the Code are yet to be notified.

The Group has assessed and accounted the incremental impact of the new Code based on the best available information and actuarial valuation amounting to Rs. 10 Crores as Exceptional item. The Group continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

5) Figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures of the full financial year and the reviewed figures upto the third quarter of the relevant financial year.

6) The Group is exclusively into Pharmaceutical business segment.

7) For List of Subsidiaries as on March 31, 2026 please refer Annexure.

Mumbai
Date: May 04, 2026



FOR WOCKHARDT LIMITED

H F KHORAKIWALA
CHAIRMAN
DIN: 00045608

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

(Rs. in Crore)

	PARTICULARS	As at	As at
		31/3/2026	31/03/2025
		Audited	Audited
A)	ASSETS		
1	Non- Current assets		
	(a) Property, Plant and Equipment	1,314	1,373
	(b) Right of use assets	304	345
	(c) Capital work-in-progress	671	513
	(d) Goodwill	1,028	977
	(e) Other intangible assets	145	41
	(f) Intangible assets under development	1,708	1,520
	(g) Financial assets		
	(i) Investments	0	0
	Rs. 0.45 crore (Previous year - Rs. 0.45 crore)		
	(ii) Other non-current Financial assets	72	53
	(h) Deferred tax assets (Net)	477	549
	(i) Non-current tax assets (Net)	85	84
	(j) Other non-current assets	114	111
	Sub-total - Non-current assets	5,918	5,566
2	Current assets		
	(a) Inventories	887	725
	(b) Financial assets		
	(i) Investments	412	422
	(ii) Trade receivables	588	661
	(iii) Cash and cash equivalents	217	112
	(iv) Bank balance (other than Cash and cash equivalents)	33	79
	(v) Other current Financial assets	51	54
	(c) Other current assets	418	412
	Sub-total - Current assets	2,606	2,465
3	Assets held-for-sale	91	104
	TOTAL ASSETS	8,615	8,135
B)	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	81	81
	(b) Other Equity	4,859	4,272
	Equity attributable to the share holders of the Company	4,940	4,353
	(c) Non - Controlling Interest	341	504
	Sub-total- Equity	5,281	4,657
2	Liabilities		
I.	Non- Current liabilities		
	(a) Financial liabilities		
	i) Borrowings	1,518	1,211
	ii) Lease Liabilities	38	95
	iii) Other non-current financial liabilities	15	-
	(b) Provisions	40	29
	(c) Deferred tax liabilities (Net)	37	35
	(d) Non-current liability - Others	64	66
	Sub-total- Non-current liabilities	1,712	1,436
II.	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	607	648
	(ii) Lease Liabilities	70	67
	(iii) Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	85	47
	Total outstanding dues of creditors other than micro enterprises and small enterprises	478	545
	(iv) Other current financial liabilities	209	429
	(b) Other current liabilities	139	238
	(c) Provisions	34	53
	(d) Current tax liabilities (Net)	6	15
	Sub-total- Current liabilities	1,622	2,042
	Total Liabilities	3,334	3,478
	TOTAL EQUITY AND LIABILITIES	8,615	8,135



Mumbai
Date: May 04, 2026



FOR WOCKHARDT LIMITED

II F KHORAKIWALA
CHAIRMAN
DIN: 00045608

WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

CONSOLIDATED AUDITED CASH FLOW STATEMENT FOR YEAR ENDED MARCH 31, 2026

		(Rs in crore)	
	PARTICULARS	YEAR ENDED 31/03/2026	YEAR ENDED 31/03/2025
	(Refer notes below)	Audited	Audited
A	CASH FLOWS FROM / (USED IN) OPERATING ACTIVITIES:		
	Profit/(Loss) after exceptional items and before tax	238	(16)
	Adjustments for :		
	Exceptional items - Impact of deconsolidation	110	-
	Depreciation and amortization expense	227	217
	Allowance/(Reversal of allowance) for expected credit loss, doubtful advance and Bad debts	(3)	38
	(Profit)/Loss on sale of fixed assets (Net)	(55)	(3)
	Gain on sale of investments	(17)	(11)
	Finance costs	213	254
	Unrealised Foreign exchange loss/ (gain), net	1	4
	Interest Income	(5)	(16)
	Employee share based payments expenses	4	1
	Liabilities no longer required written back	(7)	(22)
	Fair valuation impact on investments	(13)	(7)
	Operating profit before working capital changes	693	439
	Movements in Working capital		
	(Increase) / Decrease in Inventories	(112)	(69)
	(Increase) / Decrease in trade receivables	21	(66)
	(Increase) / Decrease in Loans and Advances and other assets	29	(192)
	(Decrease) in Liabilities and provisions	(220)	(165)
	Cash generated from operations	411	(53)
	Income tax refund / (paid)	(21)	31
	Net cash Inflow from Operating activities (A)	390	(22)
B	CASH FLOWS FROM / (USED IN) INVESTING ACTIVITIES:		
	Purchase of Property, Plant and Equipment and Capital work-in progress	(136)	(94)
	Purchase of Intangible assets and Addition in Intangible assets under development	(228)	(271)
	Proceeds from sale of property, plant and equipment (including asset held for sale)	50	10
	Margin money under lien and Bank balances (other than cash and cash equivalents)	29	(40)
	Sale/(Purchase) of current investments (net)	39	(404)
	Interest received	5	16
	Net cash Inflow / (outflow) from Investing activities (B)	(241)	(783)
C	CASH FLOWS FROM / (USED IN) FINANCING ACTIVITIES		
	Proceeds from Issuance of Equity share capital under Qualified Institutional Placement (QIP), net	-	983
	Transaction cost related to Right Issue/QIP concluded during earlier years	-	(1)
	Proceeds from Issuance of Equity share capital under ESOS* [* Rs. 0.003 crore (Previous year- Rs. 0.02 crore)]	0	0
	Proceeds from long-term borrowings	600	348
	Repayment of long-term borrowings	(130)	(353)
	Short-term borrowings (net)	(28)	(335)
	Loans from related parties- Long term	137	380
	Repayment of loans taken from related parties- Long term	(325)	(333)
	Repayment of loans taken from related parties- Short term	(42)	(46)
	Repayment of Lease liabilities (Refer note 2 below)	(71)	(70)
	Finance costs paid	(195)	(164)
	Net cash inflow / (outflow) from Financing activities (C)	(54)	409



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

CONSOLIDATED AUDITED CASH FLOW STATEMENT FOR YEAR ENDED MARCH 31, 2026

	(Rs in crore)	
NET (DECREASE) / INCREASE IN CASH AND CASH EQUIVALENTS (A+B+C)	95	(396)
Cash and cash equivalents as at the beginning of the year	112	505
Effects of exchange rate changes on cash and cash equivalents	-	1
Exchange difference on translation of foreign cash and cash equivalent	14	2
Impact of Deconsolidation	(4)	-
Cash and cash equivalents as at the end of the year	217	112
Reconciliation of cash and cash equivalents as per the cash flow statement		
Cash and cash equivalents as per above comprise of the following		
Balance with banks:		
- in current accounts	217	112
	217	112

Notes:

1. The above statement of cash flows has been prepared under the indirect method as set out in Ind AS 7 'Statement of Cash Flows'.
2. Repayment of lease liabilities consists of:
Payment of Interest ₹ 12 crore (Previous year: ₹ 16 crore)
Payment of Principal ₹ 59 crore (Previous year: ₹ 54 crore)
3. Figures in bracket indicate cash outflow.

Mumbai
Date: May 04, 2026

**FOR WOCKHARDT LIMITED**

H F Khorakiwala
H F KHORAKIWALA
CHAIRMAN
DIN: 00045608



WOCKHARDT LIMITED

Registered Office: D-4 MIDC, Chikalthana, Chhatrapati Sambhaji Nagar - 431 006
Global Headquarters: Wockhardt Towers, Bandra Kurla Complex, Bandra (East), Mumbai 400 051

List of Subsidiaries as on March 31, 2026

- 1 Wockhardt UK Holdings Limited
- 2 CP Pharmaceuticals Limited
- 3 CP Pharma (Schweiz) AG
- 4 Wallis Group Limited
- 5 The Wallis Laboratory Limited
- 6 Wockhardt Farmaceutica Do Brasil Ltda
- 7 Wallis Licensing Limited
- 8 Wockhardt Infrastructure Development Limited
- 9 Z & Z Services GmbH
- 10 Wockhardt Europe Limited
- 11 Wockhardt Nigeria Limited
- 12 Wockhardt USA LLC (upto 11th July 2025)
- 13 Wockhardt UK Limited
- 14 Wockpharma Ireland Limited
- 15 Pinewood Laboratories Limited
- 16 Pinewood Healthcare Limited
- 17 Wockhardt Holding Corp.
- 18 Morton Grove Pharmaceuticals Inc.(upto 11th July 2025)
- 19 MGP Inc.
- 20 Wockhardt Farmaceutica SA DE CV
- 21 Wockhardt Services SA DE CV
- 22 Wockhardt Bio AG
- 23 Wockhardt Bio (R) LLC
- 24 Wockhardt Bio Pty Limited
- 25 Wockhardt Bio Limited
- 26 Wockhardt Medicines Limited
- 27 Wockhardt Bioscience Limited (Formerly, Wockhardt Blonova Limited)
- 28 Wockhardt Antibiotics (Ireland) Limited (w.e.f. April 07, 2025)
- 29 Wockhardt Suisse AG (w.e.f. December 01, 2025)
- 30 Wockhardt Suisse USA Holding Corporation (w.e.f. December 11, 2025)
- 31 Wockhardt Suisse USA LLC (w.e.f. December 11, 2025)



[Handwritten signature]

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
--	---

Dear Sir/ Madam,

Subject: Declaration on Unmodified Audit Report

Pursuant to the Regulation 33(3) (d) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we hereby declare that M/s. M S K C & Associates LLP, Chartered Accountants (ICAI Firm Registration No: 001595S), the Statutory Auditors of the Company, have issued the Audit Report with unmodified opinion on the Audited Financial Results of the Company (Standalone & Consolidated) for the financial year ended 31st March, 2026.

Thanking you,
For **Wockhardt Limited**

Deepak Madnani
Chief Financial Officer